REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: RVPH) is a clinical-stage biopharmaceutical company that entered the public markets through its business combination with Tenzing Acquisition Corp., a blank-check vehicle sponsored by Tenzing Global Investors that completed its IPO in 2020. The combined company, which focuses on developing novel therapies for central nervous system disorders and respiratory diseases, began trading under the RVPH ticker following the deal's close in 2021. On May 13, 2026, the company filed an 8-K current report with the SEC under accession number 0001437749-26-016538. For full filing history, deal analytics, and real-time monitoring on RVPH and the broader SPAC universe, sign up for complete data access on SpacDesk.